Neoprobe is a biomedical company focused on enhancing patient care and
improving patient outcome by meeting the critical intraoperative diagnostic
information needs of physicians and therapeutic treatment
needs of patients.
Neoprobe currently markets the neo2000® line of gamma detection systems
that are widely used by cancer surgeons and is commercializing the Quantix®
line of blood flow measurement products
developed by its subsidiary, Cardiosonix Ltd.
In addition, Neoprobe holds significant interests in the development of
related biomedical systems and radiopharmaceutical agents including
Lymphoseek® and RIGScan® CR. Neoprobe’s subsidiary, Cira Biosciences, Inc.,
is also advancing a patient-specific cellular therapy technology platform
Neoprobe’s strategy is to deliver superior growth and shareholder return
by maximizing its strong position in gamma detection technologies and
diversifying into new, synergistic biomedical markets through continued
investment and selective acquisitions.